Immunovia AB (publ) is a leading company in the field of immunodiagnostic testing for diseases such as cancer. It is known for its commitment to innovation, accuracy, and quality. The company's corporate philosophy revolves around leveraging its expertise in biomarker-based diagnostics to provide enhanced patient care and contribute to early disease detection. Immunovia AB (publ) also values collaboration with healthcare professionals, researchers, and strategic partners to drive advancements in diagnostics. By focusing on cutting-edge technology and a patient-centric approach, Immunovia AB (publ) aims to make a significant impact in the field of healthcare and improve outcomes for patients worldwide.

Immunovia AB (publ) is primarily present in Sweden, where it is headquartered.

Immunovia AB (publ) has achieved significant milestones in its journey. The company successfully developed and commercialized IMMray™, a unique technology platform capable of detecting early-stage cancer and autoimmune diseases. Immunovia AB (publ) has also formed strategic collaborations with key players in the healthcare industry to advance its diagnostic solutions. Moreover, the company received regulatory approvals and certifications, enabling the launch of its products in various markets. Immunovia AB (publ) continues to make strides in advancing precision medicine through its innovative approach and commitment to improving early detection and patient outcomes.

Immunovia AB (publ) is a renowned biotechnology company specializing in early cancer diagnosis and prognosis using blood-based biomarker signatures. Established in 2007, the Swedish-based company has made significant advancements in detecting and predicting various types of cancer, focusing primarily on pancreatic cancer, autoimmune diseases, and other malignancies. With a robust team of experts and groundbreaking technologies, Immunovia is dedicated to offering accurate, reliable, and non-invasive diagnostic solutions that can revolutionize the field of cancer diagnostics. Through extensive research and collaborations, Immunovia aims to improve patient outcomes and contribute to advancements in personalized medicine.

The main competitors of Immunovia AB (publ) in the market include companies like Roche Holding AG, Johnson & Johnson, and Abbott Laboratories.

Immunovia AB (publ) primarily operates in the healthcare and biotechnology industries.

The business model of Immunovia AB (publ) is centered around the development and commercialization of innovative immunological diagnostic tests. The company focuses on the early diagnosis and prognosis of complex diseases, with a particular emphasis on cancer. Immunovia's proprietary technology platform, IMMray™, enables the detection and analysis of complex patterns in blood samples, allowing for the identification and prediction of diseases at an early stage. Through collaboration with healthcare providers and strategic partnerships, Immunovia aims to improve patient outcomes by providing accurate and reliable diagnostic tools.

Immunovia AB (publ) P/E-luku on 0,36.

Immunovia AB (publ) KUV on 0,19.

AlleAktien Laatuscore Immunovia AB (publ) on 6/10.

odotettu Immunovia AB (publ) liikevaihto on 628,22 milj. SEK.

odotettu Immunovia AB (publ) voitto on 320,07 milj. SEK.

Immunovia AB (publ) is a biotechnology company specializing in the development of diagnostic tests for the early detection of cancer and autoimmune diseases. The company's business model is to utilize its proprietary technologies and patents to develop and market innovative diagnostic products. The company specializes in the development of blood-based tests for detecting biomarkers that indicate various types of cancer, including pancreatic cancer, colorectal cancer, breast cancer, lung cancer, and prostate cancer. Immunovia's main product is a test called IMMray PanCan-d, specifically developed for the detection of pancreatic cancer. It utilizes a technology called protein array-based diagnostics, which analyzes antibodies in the blood. The test is capable of detecting cancer cells at a very early stage and has the potential to significantly improve patient survival rates due to its precision and effectiveness. Immunovia has also partnered with a global pharmaceutical company to bring its technology to market and commercialize it. The company plans to market its tests to both physicians and consumers and has already secured distribution agreements with partners in Europe, Asia, and the USA. In addition to cancer diagnostics, Immunovia has also developed tests for the detection of autoimmune diseases such as lupus, rheumatoid arthritis, and Sjögren's syndrome. These tests utilize similar technologies to the cancer diagnostics products and are also focused on antibodies in the blood. The accuracy of test results and the potential to detect diseases at an early stage could be groundbreaking and change the way autoimmune diseases are diagnosed. In addition to its diagnostic products, Immunovia is working on new technologies and products to further expand its business. This includes innovative methods for processing blood samples and artificial intelligence systems to improve the interpretation of test results. The goal of Immunovia is to revolutionize the diagnosis and treatment of cancer and autoimmune diseases, thereby improving the lives of patients. The company utilizes its extensive experience in researching and developing diagnostic tests, as well as its in-depth knowledge in the field of biotechnology and medical analysis. With its superior technology, wide product portfolio, and growing global presence, Immunovia could play a significant role in the prevention and early detection of cancer and autoimmune diseases in the coming years.

Immunovia AB (publ) maksaa osinkoa 0 SEK, joka jaetaan erässä vuoden aikana.

Osinkoa ei voida tällä hetkellä laskea Immunovia AB (publ):lle tai yhtiö ei maksa osinkoa.

Immunovia AB (publ):n ISIN on SE0006091997.

Immunovia AB (publ):n WKN on A2AG0F.

Immunovia AB (publ):n tunnus on IMMNOV.ST.

Viimeisen 12 kuukauden aikana Immunovia AB (publ) maksoi osinkoa edestä. Tämä vastaa noin osinkotuottoa. Seuraavan 12 kuukauden aikana Immunovia AB (publ) maksanee ennusteiden mukaan 0 SEK osingon.

Immunovia AB (publ):n tämänhetkinen osinkotuotto on .

Immunovia AB (publ) maksaa osinkoa neljännesvuosittain. Osingot jaetaan kuukausina .

Immunovia AB (publ) maksoi osinkoa joka vuosi viimeisten 0 vuoden aikana.

Seuraavalle 12 kuukaudelle odotetaan 0 SEK suuruisia osinkoja. Tämä vastaa 0 % osinkotuottoa.

Immunovia AB (publ) kuuluu sektoriin 'Terveys'.

Saadaksesi viimeisimmän Immunovia AB (publ) osingon 2.8.2024, jonka suuruus on 0 SEK, sinun oli oltava omistanut osakkeen ennen ex-päivää, joka oli 2.8.2024.

Viimeisin osinko maksettiin 2.8.2024.

Vuonna 2023 Immunovia AB (publ) maksoi 0 SEK osinkoina.

Immunovia AB (publ):n osingot maksetaan SEKssa.